DCP
HUMAW icon

Diameter Capital Partners’s Humacyte Inc Warrant HUMAW Stock Holding History

Diameter Capital Partners’s Portfolio HUMAW Stock Details HUMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,085
Closed -$37K – 42
2022
Q1 		$37K Sell
19,085
-4,772
-20% -$8.06K ﹤0.01% 58
2021
Q4 		$54K Buy
+23,857
New +$69.7K ﹤0.01% 145

Other funds holding HUMAW

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Diameter Capital Partners's HUMAW Position: Q2 2022 in Review

Diameter Capital Partners sold out of Humacyte Inc Warrant (HUMAW) in Q2 2022, closing a stake of 19,085 shares — an estimated $37K sold.

Diameter Capital Partners first reported a position in HUMAW in Q4 2021 and held it in 2 quarters. The position peaked at $54K in Q4 2021. 12 funds tracked by Wall St. Rank hold HUMAW as of Q2 2022.

  • Diameter Capital Partners reported no remaining Humacyte Inc Warrant position as of Q2 2022 after selling out during the quarter.
  • Diameter Capital Partners sold 19,085 Humacyte Inc Warrant shares in Q2 2022, an estimated $37K.
  • Diameter Capital Partners first reported a position in Humacyte Inc Warrant in Q4 2021 and held it in 2 quarters.
  • Diameter Capital Partners's Humacyte Inc Warrant position peaked at $54K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q2 2022.

Based on Diameter Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.